By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > News > Bayer shares plunge after blood-thinning drug trial halted
News

Bayer shares plunge after blood-thinning drug trial halted

News Room
Last updated: 2023/11/20 at 6:26 AM
By News Room
Share
4 Min Read
SHARE

Unlock the Editor’s Digest for free

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.

Bayer shares plunged to their lowest level in more than a decade after the group abandoned a key late-stage trial of a blood-thinning drug that was seen as a prospective blockbuster, saying it did not work as hoped.

The German company on Monday said its Oceanic trial studying asundexian as a treatment for atrial fibrillation had shown “inferior efficacy” compared with standard treatment.

Over the weekend, Bayer also lost a key case in the US related to the weed killer Roundup, which it acquired when it bought Monsanto in 2016. Shares fell as much as 20 per cent in morning trading on Monday, their biggest-ever drop, reaching lows not seen since 2008. More than €7.5bn in market value was wiped off the company within hours.

The abandoned asundexian trial “is a major setback for Bayer”, said Markus Manns, a portfolio manager and healthcare expert at Union Investment, Germany’s third-largest asset manager. Manns said asundexian was the most promising drug in Bayer’s pharma pipeline. “Without it, the pharma unit is left without sustainable growth.”

Bayer’s pharma unit is facing the expiry of patents on some of its best-selling drugs, including its anti-clotting medication Xarelto, and had high hopes for asundexian. The company previously estimated that the new drug could generate up to €5bn in sales a year — a quarter of the group’s entire 2022 pharma revenue.

Bayer said it had decided to end the trial on the recommendation of an independent committee monitoring the study. It said it would “further analyse the data to understand the outcome” and publish it. The company said it would continue to study the drug in a separate trial for stroke patients.

Analysts at Barclays said they saw the failure as “a total surprise” and downgraded the stock.

Shares in Bayer have underperformed since the group’s €63bn takeover of US agrochemical giant Monsanto, which saddled the company with debt and exposed it to costly and drawn-out litigation over allegations that Roundup causes cancer, which Bayer denies.

Bayer has already paid more than $10bn to settle claims related to the best-selling weedkiller and has earmarked another $6.4bn for future legal costs. After winning nine consecutive court cases over the past years, it has suffered a string of defeats in US courts since the summer.

Bayer said it would appeal against the verdicts and accused plaintiffs of having misrepresented “worldwide regulatory and scientific support for our products” in court, adding that it had “strong arguments to get the recent unfounded verdicts overturned”.

Bayer replaced its chief executive earlier this year, hiring former Roche executive Bill Anderson, who has promised to explore “all options” for the struggling group, including splitting the pharma unit from the crop sciences business. He has also promised to make the business less bureaucratic and more efficient.

The abandoned trial and the court loss compound the challenges facing Anderson, who recently said the conglomerate’s performance was “not acceptable” as it struggled to revive its fortunes after the Monsanto deal.

Read the full article here

News Room November 20, 2023 November 20, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
The nuclear mountain that haunts Israel

To Israeli military planners, it is akin to Mount Doom: a tightly…

Israeli attacks revive bitter Iranian memories of 1980s Iraq war

On the first night of Israel’s air strikes on Tehran, Sanam, a…

Carmakers seek western supplies of rare earths and magnets

Stay informed with free updatesSimply sign up to the Automobiles myFT Digest…

Why Saudi Arabia raised oil output before Israel’s attack on Iran

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

Israel-Iran latest: Iran and Israel exchange fresh strikes as conflict escalates

Iran’s Revolutionary Guards have threatened “more forceful and expansive” attacks against Israel…

- Advertisement -
Ad imageAd image

You Might Also Like

News

The nuclear mountain that haunts Israel

By News Room
News

Israeli attacks revive bitter Iranian memories of 1980s Iraq war

By News Room
News

Carmakers seek western supplies of rare earths and magnets

By News Room
News

Why Saudi Arabia raised oil output before Israel’s attack on Iran

By News Room
News

Israel-Iran latest: Iran and Israel exchange fresh strikes as conflict escalates

By News Room
News

Two Alternatives For A Potential $5,000 Monthly Income

By News Room
News

Thousands protest across US against Trump’s ‘authoritarian’ policies

By News Room
News

Iran strikes leave Israelis shaken but resolute

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?